Navigation Links
Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
Date:5/12/2008

f an in-clinic, multi-center, randomized,

double-blind, single administration, placebo-controlled Phase 2a

proof-of-concept clinical trial in 168 migraine patients with or

without aura. Three doses of AZ-104 (1.25, 2.5 and 5 mg) were

evaluated against placebo in the clinical trial. Using the IHS

4-point rating scale, the primary efficacy endpoint was pain-relief

response at 2 hours post-administration. AZ-104 met the primary

efficacy endpoint of the clinical trial for the two highest doses of

the drug compared to placebo. Statistically significant

improvements in pain response were observed in 76.7% of patients at

the 5 mg dose (p=0.02), 79.1% of patients at the 2.5 mg dose (p=0.01)

and 67.4% of patients at the 1.25 mg dose (p=0.18), compared to 51.3%

of patients receiving placebo. AZ-104 has been licensed to Symphony

Allegro and the Company has the right to repurchase all rights to this

product candidate.

-- AZ-002 (Staccato alprazolam). Alexza is developing AZ-002 for the

acute treatment of panic attacks associated with panic disorder. The

Company completed enrollment of its Phase 2a proof-of-concept clinical

trial in patients with panic disorder in April 2008. Alexza expects

to report initial results of this trial by the end of the second

quarter of 2008. AZ-002 has been licensed to Symphony Allegro and the

Company has the right to repurchase all rights to this product

candidate.

-- AZ-003 (Staccato fentanyl). Alexza is jointly developing AZ-003 with

Endo Pharmaceuticals Inc. for the treatment of breakthrough pain in

cancer and non-cancer patients. Endo is responsible for regulatory,

pre-clinical and clinical development, and for commercializing the

product in North America. Alexza is respons
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
2. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
3. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
4. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
5. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
6. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
7. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
8. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
9. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
10. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
11. MGT Capital Investments Reports First Quarter 2008 Financial Results and Provides Update on Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... NASA’s MESSENGER has just celebrated its 10 ... to have one of its latch valves, V27200-818, operating ... scientific investigation of the planet Mercury. It is only ... has provided a vast amount of information and images ... valves utilize solenoids that also include permanent magnets to ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 “Nature has ... the features that we desire in optical design,” said ... Montana State University. “As we explore surfaces and structures ... those lessons were presented in San Diego in August ... Light in Nature ” chaired by Shaw and Rongguang ...
(Date:9/16/2014)... -- Biocom, the association representing the Southern California ... Annual National Health Information Technology Week, which brings ... our health care system. " ... most vibrant hubs for health IT and digital health ... testing to remote patient monitoring," said Joe Panetta ...
(Date:9/16/2014)... who created a deicing film for radar domes have ... coating for glass. , The new work by ... glass surfaces from windshields to skyscrapers free of ice ... (RF). , The technology was introduced this month ... and Interfaces . , The material is made ...
Breaking Biology Technology:Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5Biocom Recognizes National Health IT Week 2Nanoribbon film keeps glass ice-free 2
... Global Products, BASINGSTOKE, England, October 8 ... global specialty biopharmaceutical,company, announces that it has agreed ... Almirall for a cash consideration of $213m. The ... sodium),and VANIQA(R) (eflornithine hydrochloride), and six other non-promoted,products1 ...
... about the origins of quantum dot blinking, researchers ... Laboratory, the University of Chicago and the California ... characterize it on faster time scales than have ... also known as quantum dots, are being intensively ...
... to Vice President, Research Operations ... Non-Profit Foundation, CARLSBAD, Calif., Oct. 5 ... focused on the discovery and,development of small-molecule therapeutics ... diseases, today announced changes to its,research management. Dr. ...
Cached Biology Technology:Shire Divests Non-Core Product Portfolio to Almirall 2Shire Divests Non-Core Product Portfolio to Almirall 3Argonne researcher studies what makes quantum dots blink 2Ardea Biosciences Announces Changes to Research Management 2Ardea Biosciences Announces Changes to Research Management 3
(Date:9/17/2014)... R.I. [Brown University] After decades of decline, grasses ... saltmarshes. To the eye, the marsh in those places ... that a key service of the marsh coastal ... back but the ecosystem function hasn,t come back," said ... senior author of the study in the journal ...
(Date:9/17/2014)... been growing significantly faster since the 1960s. The typical ... but they have accelerated -- by as much as ... carried out by scientists from Technische Universitt Mnchen based ... been continuously observed since 1870. Their findings were published ... ago, "forest dieback" was a hot topic, with the ...
(Date:9/17/2014)... United Kingdom forms a new crime unit designed to ... last year over horse meat being passed off as ... for detecting meat adulteration. They describe their approach, which ... Journal of Agricultural and Food Chemistry . , ... a major global economic problem. But they also say ...
Breaking Biology News(10 mins):Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3
... University of Delaware have developed a "smart" hydrogel that can ... Over the past few decades, smart hydrogels have been created ... "The idea of a smart hydrogel that can release ... professor of materials science and engineering and biomedical engineering. "What,s ...
... Living organisms have adapted to the day-night cycle and, in ... are not completely known yet but its functioning has been ... of normal circadian rhythms can have deleterious effects on health; ... the time of feeding was shown to affect the ability ...
... of the white-throated sparrow has identified a biological pathway connecting ... wild to variation in their genome. The Proceedings ... is publishing the results of the experiments, conducted by the ... Psychology. The research, which comprised behavioral observations ...
Cached Biology News:UD-developed smart gels deliver medicine on demand 2The internal clock and feeding rhythm set the pace of the liver 2Wild sparrow study traces social behaviors in the field to specific gene 2Wild sparrow study traces social behaviors in the field to specific gene 3Wild sparrow study traces social behaviors in the field to specific gene 4
... Anti-Natural Killer Cell Receptor-P1, ... Immunogen: Hybridoma produced ... from BALB/c mice immunized (BALB/c ... (LAK) cells and mouse myeloma ...
... Yersinia pestis This antibody is ... Immunogen: Purified F1 ... vaccine strain EV76. Specificity: ... capsular antigen. There is no cross-reactivity ...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Anti-human C3a/C3a des-Arg (neo-epitope), Clone 2991, Monoclonal Antibody...
Biology Products: